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Abstract 
 
Decorin binding protein A (DBPA) is an important surface adhesin of the bacterium 
Borrelia burgdorferi, the causative agent of Lyme disease. DBPA facilitates the bacteria’s 
colonization of human tissue by adhering to glycosaminoglycan (GAG), a sulfated 
polysaccharide. Interestingly, DBPA sequence variation among different strains of Borrelia 
spirochetes is high, resulting in significant differences in their GAG affinities. However, the 
structural mechanisms contributing to these differences are unknown. We determined the 
solution structures of DBPAs from strain N40 of Borrelia burgdorferi and strain PBr of Borrelia 
gariini, two DBPA variants whose GAG affinities deviate significantly from strain B31, the best 
characterized version of DBPA. Our structures revealed that significant differences exist between 
PBr DBPA and B31/N40 DBPAs. In particular, the C-terminus of PBr DBPA, unlike C-termini 
from B31 and N40 DBPAs, is positioned away from the GAG-binding pocket, and the linker 
between helices one and two of PBr DBPA is highly structured and retracted from the GAG-
binding pocket. The repositioning of the C-terminus allowed the formation of an extra GAG-
binding epitope in PBr DBPA, and the retracted linker give GAG ligands more access to the 
GAG-binding epitopes than other DBPAs. Characterization of GAG ligands’ interactions with 
wild type PBr and mutants confirmed the importance of the second major GAG-binding epitope 
and established the fact that the two epitopes are independent of one another and the new epitope 
is as important to GAG binding as the traditional epitope.  
 
Introduction 
 
Glycosaminoglycans (GAGs) are extracellular sulfated polysaccharides ubiquitous to all 
mammals. GAGs have diverse bioactivities and play a vital role in physiological phenomena 
ranging from blood coagulation and inflammation to cell differentiation and growth. GAGs are 
also targeted by bacteria and viruses as entry points to cells or as anchors for establishing 
residency.[1-3] One of these microbes is the bacterium Borrelia burgdorferi, the causative agent 
of Lyme disease. B. burgdorferi is an extracellular bacterium that depends on strong associations 
with components of extracellular matrix for secure attachment to tissues. To accomplish this, B. 
burgdorferi has evolved to have a number of different adhesins targeting the extracellular 
matrix.[4, 5] Among the most well studied of these is decorin-binding protein A (DBPA). DBPA 
was first identified as the adhesin responsible for binding to the proteoglycan decorin, an 
essential component of connective tissues.[6, 7] Later studies showed the GAG portion of 
decorin is the major binding site of DBPA, although the possibility of the core protein also being 
part of the binding epitope has not been ruled out. Even though the type of GAG found on 
decorin is mostly dermatan sulfate (DS), DBPA has also been known to bind other types of 
GAGs including heparin and heparan sulfate.[8] In fact, DBPA’s affinity for heparin is 
considerably higher than that for DS [8, 9]. 
One particularly interesting feature of DBPA is that the sequence variation of DBPA 
among different strains of Borrelia genospecies is large, with pair-wise sequence identities 
ranging from 60 to 99.5 %.[10, 11] This magnitude of genetic variations is not observed in 
DBPA’s close homologue, decorin binding protein B (DBPB), which is conserved across 
Borrelia spirochetes. Studies carried out by Leong and co-workers on DBPAs from several 
strains of Borrelia spirochetes indicate the affinities of different versions of DBPA vary greatly 
and confer different tissue preferences.[11, 12] Their results demonstrated that DBPA from the 
PBr strain of B. garinii binds to decorin and DS with high affinity (KD ~ 0.16 μM for intact DS) 
while affinity of B31 DBPA for the same ligands are lower (KD ~ 0.63 μM for intact DS), and 
DBPA from strain N40 has the weakest DS affinity among the three (KD ~ 2.58 μM for intact 
DS).[11] Although the GAG-binding epitopes of B31 and N40 versions of DBPA have been 
investigated [13, 14], very little is known about the GAG-binding epitopes of PBr DBPA and the 
mechanisms by which it achieves its higher GAG affinities. 
Knowing the mechanisms leading to the GAG affinity differences among DBPA variants 
are not only important to understanding the role of this protein in promoting bacterial adhesion, it 
may also help in designing DBPA-based tools for combating Borrelia bacteria. In particular, 
because of DBPA’s strong tendency to induce human immune response, it has been considered 
as a component in vaccines and serological tests for Lyme disease.[15] However, the large 
sequence variation in DBPA may require the inclusion of several versions of DBPA to elicit 
comprehensive immunity against all strains since sequence variations in DBPA may prevent 
antibodies against DBPA of one strain from detecting other versions. Understanding of the 
structural differences and similarities among the different strains will aid in the intelligent 
selection of representative DBPA variants that can present greatest coverage in these tests. The 
family of DBPA proteins also provides an excellent opportunity to study diversity in GAG-
binding motifs. Understanding of the structure-activity relationships of GAG-binding proteins is 
still rudimentary. DBPAs share a similar tertiary fold, therefore GAG affinity differences should 
come mainly from differences in arrangements of GAG-binding residues on this common frame. 
This allows the effects of spatial arrangement of basic amino acids on the protein’s affinity and 
specificity for GAGs to be investigated. 
Previously, structure-activity relationships of DBPAs from the closely related strains of 
B31and 297 have been investigated by us and other groups.[9, 14, 16] To further understand the 
correlation of DBPA sequence variation with differences in GAG affinities, we have determined 
the solution structures for N40 and PBr strains of DBPA, and analyzed the interactions of these 
proteins with GAG ligands. The structures of both proteins retain the five helical bundle fold of 
B31 DBPA, with the N40 DBPA structure being almost identical to that of B31 DBPA. 
However, the structure of PBr DBPA contains significant differences compared to B31 DBPA. 
In particular, the flexible linker between helices one and two adopts a helical conformation in 
PBr DBPA while the same segments in B31 and N40 are mostly unstructured. In addition, the C-
terminal tail of PBr DBPA has a different orientation than those found in B31 and N40 DBPAs. 
The functional consequences of these changes are that, unlike B31 and N40 DBPAs, which 
contains only a single GAG-binding epitope, PBr DBPA contains at least two independent 
binding epitopes. While the location of one epitope is similar to the major GAG-binding epitopes 
found in B31 and N40 versions of the protein, the other epitope in PBr DBPA is located on the 
opposite side of the helical bundle, outside the canonical binding pocket for DBPA. Quantitative 
analysis of binding dissociation constants using NMR and other techniques showed that the new 
epitope has as high an affinity for GAGs as the epitope in the traditional binding pocket, and the 
two epitopes are completely independent of one another. Our results show that the mechanisms 
of GAG-binding vary greatly among different DBPA variants, and detailed structural study will 
be required to fully understand the GAG-binding mechanisms of each. 
 
Experimental 
 
Expression and purification of B31, N40, and PBr DBPAs 
The open reading frames (ORFs) for the wild-type (WT) mature DBPA strains B31 
(residues 24-191), N40 (residues 29-194) and PBr (residues 22-185) were synthesized by 
GenScript Inc. (Piscataway, NJ). Each ORF was cloned into the pHUE vector which results in a 
fusion protein of His-tagged ubiquitin at the N-terminus of each DBPA. PBr mutants were 
created using site-directed mutagenesis from the WT sequence. The forward primers for Site 1 
and Site 2 are the following:  K79S, 5'-
GCCGGAATTTATCCTGAAAGCCAGCATTAAAGCAATCCAAGTGGC-3'; K130S, 5'-
CTGGAAGAAATTGGCATCCAGAGCATGACCGGTACGGTG-3'; K160S, 5'-
GCCCAGGCAATGGAAGACAGCCTGAACAATGTCAAC-3'; K77,81S, 5'-
CCGGAATTTATCCTGAGCGCCAAGATTAGCGCAATCCAAGTGGCTG-3'; K173,176S, 
5'-CAACATGATGCGCTGAGCAATCTGAGCGAAAAAGCTAAGACCGCG-3'. 
Incorporation of the correct mutations was confirmed through sequencing. 
Each plasmid was transformed into E. coli BL21(DE3) and then the bacteria was grown 
at 37°C to an OD600 of 0.5. Unlabeled protein was grown in normal LB while isotopically 
labeled protein was grown in M9 medium supplemented with 
15
NH4Cl or [
13
C] glucose. The 
bacteria were induced with 0.5 mM IPTG and incubated overnight at 30°C. After the cells had 
been harvested, the resuspended pellet was incubated with 1 mg/mL lysozyme and sonicated to 
lyse the cells. The fusion protein was extracted from the cleared supernatant via Ni affinity 
chromatography with a 5 mL HisTrap column (GE Life Sciences) and was eluted using an 
imidazole gradient of 25 mM to 300 mM at a flow rate of 3 mL/min. The fusion protein was 
collected and exchanged into 25 mM Tris (pH 8.0), 100 mM NaCl and was digested with USP2 
and 1 mM DTT overnight at room temperature. The cleaved DBPA was separated using a 5 mL 
HisTrap column and was eluted in the flow-through which was then collected, concentrated and 
exchanged into 20 mM acetate pH 5.0, 150 mM NaCl. 
 
Acquisition and analysis of NMR structural data for N40 and PBr DBPAs 
NMR data for N40 and PBr structure determination were collected on Varian Inova 800 
MHz, Bruker Ultra-Shield 600 and 850 MHz spectrometers. Many of the pulse sequences were 
included in the pulse sequence packages BioPack and TopSpin. HNCACB, CBCACONH, 
HNCOCA, and HNCO experiments were collected for backbone atom assignment. For side 
chain atom assignments, CCONH, HCCONH, HCCH-TOCSY, 
15
N-edited TOCSY, and 
13
C- and 
15
N-edited NOESY-HSQC spectra were collected. Both HN and NC RDCs were collected using 
J-modulated pulse sequence on both proteins aligned in 6% polyacrylamide gel.[17] Data 
processing was conducted with NMRPipe and analyzing was done with NMRView. 
Relaxation and paramagnetic relaxation enhancement experiments were collected on Bruker 
Ultra-Shield 600 MHz and Varian Inova 800 MHz spectrometers. T1, T2, and steady-state 
heteronuclear NOE experiments were collected for both WT N40 and PBr with and without 24 
molar equivalents of heparin dp6. NMRPipe[18] was used to process and NMRView[19] was 
used to analyze the data. The order parameter (S
2
) was extracted for each protein using relax, 
model-free software.[20] PRE of TEMPO-tagged heparin dp6 was measured from 
1
H T2 of 
backbone amide protons.[21] For the N40 PRE experiment, 6 molar equivalents of TEMPO-
tagged heparin dp6 was added to 400 µL of 150 µM protein while 2 molar equivalents were 
added to 400 µL of 300 µM PBr. Contribution of the TEMPO radical was seen in the difference 
between 
1
H T2 before and after reduction of the radical with 10 molar equivalent of ascorbate. 
 
Structure determination for N40 and PBr DBPAs 
Both 
13
C and 
15
N isotopically edited NOESY-HSQC data were analyzed and assigned, 
primarily to identify long-range contacts. Backbone dihedral angles of the α-helical residues 
were calculated using TALOS.[22] The NOESY-HSQC peak lists as well as the dihedral angles 
were used in CYANA to determine each structure.[23] The resulting structure with minimal 
long-range violations, along with RDCs, was refined in XPLOR-NIH.[24] Surface electrostatic 
potential of N40 and PBr DBPAs at an ionic strength of 150 mM were calculated with the 
program APBS.[25] 
 
Production and modification of heparin and heparin fragments 
Heparin (Sigma Aldrich) was dialyzed and lyophilized to remove excess salt prior to 
being digested with heparinase I. Digestion was allowed to continue until depolymerization was 
approximately 30% complete to give fragments of varying size. These fragments were separated 
via size exclusion chromatography on a 2.5 cm x 175 cm column (Bio-Rad Biogel P10) with a 
flow rate of 0.2 mL/min. Each fragment was collected, dialyzed, and lyophilized prior to HPLC 
verification of fragment size. The fragments were quantified gravimetrically or with a carbazole 
assay [26]. The reducing end of heparin dp6 (degree of polymerization 6, i.e. hexasaccharide) 
was modified with 4-amino-TEMPO, a nitroxide radical, through reductive amination.[14] This 
TEMPO-labeled GAG fragment was used for the PRE study. 
 
Titrations of DBPA variants with heparin dp6 
NMR-monitored titration was used to estimate the KD values for the interaction between 
heparin dp6 and DBPA variants analyzed in this study. For each PBr titration, 14 molar 
equivalents of heparin dp6 were added to 400 µL of 150 µM protein in 2 molar equivalent 
aliquots; whereas the titration of N40 involved the addition of 25 molar equivalents of heparin 
dp6 to 400 µL of 150 µM protein in 5 molar equivalent aliquots. This was conducted in 150 mM 
NaCl, 20 mM acetate buffer at pH 5.0 for WT N40, WT PBr as well as PBr Site 1, Site 2a, and 
Site 2b. The chemical shift changes noted in each 
1
H-
15
N HSQC were normalized into one 
chemical shift value using the equation, 𝛿𝐻 = [∆𝛿𝐻
2 + 1.7∆𝛿𝑁)
2]1/2, where δH and δN represent 
the chemical shifts for 
1
H and 
15
N, respectively.[27] The KD binding curves were fitted in xcrvfit 
(http://www.bionmr.ualberta.ca/bds/software/xcrvfit/) to plot the normalized chemical shift 
against the heparin dp6:DBPA ratio. 
1
H-
15
N HSQC spectra were collected on a Bruker Ultra-
Shield 600 MHz spectrometer. 
 
Gel mobility shift assays for WT B31, N40, PBr and PBr mutants 
Heparin dp8 fragments were fluorescently labeled with 0.1M 2-aminoacridone (2-
AMAC) according to the method of Lyon et al.[28] The wildtype (WT) DBPA assay was 
performed by mixing 1 µg of the fluorescently labeled heparin dp6 with 0.5, 1 or 2 molar 
equivalents of either B31, N40 or PBr DBPA in 50 mM sodium phosphate (pH 6.5), 150 mM 
NaCl buffer for a total volume of 12.5 µL. The PBr mutant assay was performed by mixing 1 µg 
of the fluorescently labeled heparin dp8 with 1 or 2 molar equivalents of DBPA in 50 mM 
sodium phosphate (pH 6.5), 150 mM NaCl buffer for a total volume of 12.5 µL. The control for 
both assays is protein-free fluorescent heparin dp6 or dp8 fragments. The reaction mixtures were 
incubated at room temperature for 30 minutes then were run in a 1% agarose gel at 120 V for 15-
25 minutes. A UV panel was used to visualize the shifts.[29]  
 
Enzyme-linked immunosorbent assay (ELISA) analysis of heparin binding to WT PBr and 
PBr mutants 
Intact heparin was biotinylated and quantified with the Biotinylation Quantitation kit 
(Pierce) according to manufacturer’s instructions. Neutravidin-coated microplates (G-
Biosciences) were coated with 100 µL of PBS containing 20 µg/mL of biotinylated heparin and 
were incubated with 2 ug of His-tagged WT PBr and PBr mutants in 100 µL PBS. The results 
were quantified using 1:2000 Anti-His HRP (Qiagen) and developed with tetramethylbenzidine 
(TMB) substrate solution. An additional 100 µL of 0.1 M HCl was added to each well to stop the 
reaction which induced a color change thus allowing the plate to be read at 450 nm. 
Competitive heparin-binding ELISA for PBr DBPA variants and biotinylated N40 DBPA 
N40 DBPA was biotinylated by reacting carboxyl side chains in N40 DBPA with amino-
PEG2-biotin (Thermo Scientific). Specifically, 1 mL of 26 μM of N40 DBPA was treated with 
2.6 mM of EDC and 5.2 mM of amino-PEG2-biotin for 30 minutes at room temperature. Excess 
biotin and EDC were then removed by desalting the mixture with a HiTrap Desalting column 
(GE Healthcare). The competition ELISA was carried out by first incubating commercially 
available heparin-coated microwell plates (Bioworld) with 100 μL per well of PBS containing 4 
μg of biotinylated N40 DBPA and either 0, 2, 4 or 6 μg of PBr DBPA variants for 1 hour. The 
amount of bound N40 DBPA was then determined by incubating the wells with streptavidin-
HRP (Cell Signaling Inc.) for 1 hour, and followed by treatment with TMB reagents for 20 
minutes before the absorbance at 450 nm was measured. 
 
Results 
 
Structural differences among DBPAs of strains B31, N40 and PBr 
Solution structure of B31 DBPA is comprised of a five-helix bundle with unstructured 
segments between the first two helices and at the C-terminus.[9] The crystal structure of DBPA 
from strain 297 adopts an identical fold [16]. Building on these investigations, we have 
determined the solution structures of DBPA from strain N40 of Borrelia burgdorferi and strain 
PBr of Borrelia gariini, two variants that have significantly different GAG affinities than B31 
DBPA.[11, 12] Structural statistics for these two structures are shown in Table 1. It is evident 
from these structures that N40 and PBr DBPAs have similar helical topologies and hydrophobic 
packings as B31 DBPA (Figure 1). Sequence alignment of all three DBPAs indicates that, 
despite the low sequence identity between PBr and B31 DBPAs, all three DBPAs share 
remarkably similar secondary structural element arrangements (Figure 2). Analysis of 
hydrophobic contacts within each structure showed that both N40 and PBr DBPAs are stabilized 
by the presence of a hydrophobic core formed with hydrophobic amino acids from helices 2, 3, 
and 5. The same hydrophobic core is also present in B31 DBPA. 
Figure 3 shows the superimposition of B31, N40 and PBr DBPA structures. Both N40 
and PBr DBPA structures superimposed with the B31 DBPA structure very well. RMSD 
between helical residues of B31 DBPA and N40 DBPA is 1.9 Å, and RMSD between helical 
residues of B31 DBPA and PBr DBPA is 2.3 Å. Despite the similarities in the helical regions, 
structure of PBr DBPA differs significantly from B31 and N40 DBPAs in two respects. 
Specifically, the linker between helices 1 and 2 of PBr DBPA (residues 56 to 67) adopts a helical 
conformation while the same region in B31 and N40 DBPA is mostly unstructured (Figure 3). 
The helical nature of PBr DBPA’s linker was confirmed by the values of backbone dihedral 
angles of the linker residues predicted using TALOS+ [30] and by the presence of NOEs 
between sequential amide protons, which are reliable indicators of helical conformation. The 
structural consequence of such a conformation change is that the PBr DBPA linker is more 
compact than those in B31 & N40 DBPAs. In addition, PBr does not contain the disulfide bond 
connecting the C-terminus and helix 5, which is present in both B31 and N40 DBPAs. This 
allows the C-terminus of PBr to be less restricted and to point away from the canonical GAG-
binding pocket (Figure 3). It should also be noted that both N40 and PBr are missing the basic 
amino acid cluster (the BXBB motif) in the flexible linker, which is known to be important for 
GAG-binding in B31 DBPA. [14]  
Because GAG-protein interactions are mediated mostly by electrostatic interactions 
between sulfate or carboxyl groups on the polysaccharide and basic amino acids on the protein, a 
surface electrostatic potential map of the protein is often a good way to identify possible GAG-
binding epitopes. Electrostatic potential mappings of N40 and PBr DBPAs confirmed the 
presence of a basic pocket formed by helices 1, 2 and 5 (Figures 4 and 5) of both proteins. This 
basic patch, which contains three lysine residues (K82, K163 and K170 in B31 DBPA; K85, 
K166 and K173 in N40 DBPA) known to be crucial to GAG binding, has also been identified as 
the primary site for DBPA-GAG interactions in both B31 and 297 DBPAs.[13, 14, 16] It is 
notable that the linker in N40 and B31 DBPAs almost entirely obscures this basic pocket. 
However, the helical nature of the linker in PBr results in a more exposed basic patch than in 
B31 and N40 DBPAs (Figure 5). Besides the three conserved lysines (K79, K160, and K167) in 
the canonical binding site (Site 1), the electrostatic potential map of PBr also indicates the 
possible existence of a second GAG-binding epitope composed of residues K44, K77, K81, 
K173, and K176 (Site 2) (Figure 5). This site is located on the opposite side of the helices as Site 
1, and is not found in B31 or N40 DBPAs. 
 
GAG’s interaction with WT N40, B31 and PBr DBPAs 
Previous studies by Leong and co-workers have provided comprehensive analyses of the 
differential binding affinities of the DBPA variants.[11, 12] Specifically, PBr DBPA has the 
highest affinity for both decorin and DS, while B31 DBPA shows a slightly weaker affinity, and 
N40 DBPA has the weakest affinity for these ligands. We also carried out a qualitative 
comparison of DBPA-heparin hexasaccharide (dp6, degree of polymerization 6) interactions 
among the three strains with a gel mobility shift assay (GMSA), an experiment based on the 
principle that the migration of heparin dp6 in electrophoresis will be impeded upon binding to 
DBPA. Figure S1 shows the results of the assay. After the addition of one molar equivalent of 
protein to fluorescently labeled heparin dp6, both B31 and PBr DBPAs produced shifts in the 
positions of a significant fraction of heparin dp6 fragments. In contrast, N40 DBPA induced 
shifts in a much smaller fraction of heparin dp6, indicating GAG affinity of N40 DBPA is lower 
than that of B31 and PBr DBPAs. These results are consistent with previous studies.[11, 12]  
In order to verify the involvement of the proposed GAG-binding epitopes in binding 
GAGs, WT PBr’s interaction with heparin dp6 was examined via NMR-monitored titration. 
Although DS is the GAG-type most commonly found on decorin, our choice of GAG ligands 
was limited by the fact that solution NMR studies cannot be conducted using natural 
polysaccharides because of the protein aggregation induced by the long polymers. As a result, 
only short GAG ligands can be used in these titrations. However, the use of short ligands 
diminishes the avidity effect that protein-GAG interactions rely on to achieve high affinity. Our 
previous studies have shown that DBPA’s affinity for DS dp6 is very low (KD > 10 mM), thus 
not ideal for identifying GAG-binding epitopes. To improve the binding affinity, we chose to use 
heparin dp6 as our ligand. We have used these ligands previously [9, 14], and DBPAs’ relative 
affinities for these ligands correlate well with their affinities for intact DS in our experience.  
In the titrations of both N40 and PBr DBPAs with heparin dp6, significant changes in the 
chemical shifts of amide protons and nitrogens were seen (Figure 6). However, N40 DBPA 
required more ligands to produce shifts of similar magnitudes as PBr DBPA. Because 
magnitudes of chemical shift changes are a good indication of involvement in ligand binding, 
these values are often used to identify residues in the GAG binding sites. Figure 6 shows the 
residue-specific changes in amide proton and nitrogen chemical shift changes for both N40 and 
PBr DBPAs. Residues N68, T90 and C191 in N40 DBPA produced the biggest changes in 
chemical shifts. These residues are found in the linker, helix 2 and the C-terminus, all are around 
the basic GAG-binding pocket (Figure 6A). Residues E57, L76, K130, L175, E177, and A179 in 
PBr DBPA showed the most changes in chemical shifts upon the addition of heparin dp6. These 
residues are found in helix 2, the linker between helices 3 and 4, as well as the C-terminus 
(Figure 6B). Most of which are located near either Site1 or Site 2. It should also be noted that 
none of the residues in the linker regions of PBr showed large changes in their chemical shifts. 
This is significantly different from what has been observed in B31 DBPA.[9]  
Besides identifying possible GAG-binding epitopes, we also obtained the KDs of 
interaction for these proteins by measuring the magnitudes of chemical shift changes induced by 
different concentrations of heparin dp6. The KD for N40 DBPA’s interactions with heparin dp6 
was calculated to be greater than 4 mM for most residues with large chemical shift changes 
(Figure S2). In contrast, KD of interaction for B31 DBPA and heparin dp6 is ~ 0.5 mM.[14] 
Heparin dp6 binding curves of PBr DBPA residues differed significantly and did not produce a 
consensus KD value. For residues near Site 1 (T64, K130, G133), the binding curve showed the 
site was not saturated at high heparin dp6 concentrations (Figure S3), indicating the GAG 
affinity of the site is low. However, another group of residues at the C-terminus (A179 & A182), 
near Site 2, produced binding curves that showed much higher affinity for GAGs and quick 
saturation (Figure S3). Fitting binding curves independently and assuming that the concentration 
of the free ligand is not affected significantly by the presence of the other binding site, which is 
valid because the ligand is present in much higher excess than the protein throughout the 
titration, we obtained KD of ~ 1.2 mM for Site 1 residues, and ~ 0.4 mM for Site 2 residues. 
To estimate GAG-binding induced changes in conformational dynamics of the proteins, 
we used the Model-Free approach [14, 31, 32] to measure the flexibility of the protein backbone 
in the presence and absence of the GAG-ligands. The Model-Free approach combines NMR 
observables such as longitudinal relaxation rates, transverse relaxation rates, and steady state 
heteronuclear NOE of the atom to derive a parameter known as the order parameter, or S
2
. 
Values of S
2
 range from values 0 to 1, with 1 indicating the atom is in a region of protein having 
rigid conformation and 0 indicating the atom is in a completely flexible segment of the protein. 
We measured the S
2
 values of backbone amide nitrogen atoms in the presence and absence of the 
heparin dp6 ligand for both N40 and PBr DBPAs. No large changes in S
2
 were observed in either 
protein, indicating that backbone dynamics remain unaffected by GAG-binding (Figure S4).  
Although chemical shift mapping is widely-used to define ligand binding epitopes, other 
phenomena in the protein, such as ligand-induced conformation changes, can produce artifacts 
that maybe misleading. To unambiguously define the GAG-binding epitope, we also probed the 
protein with heparin dp6 ligands functionalized at the reducing end with the nitroxide radical 
TEMPO.[14] The paramagnetic center of TEMPO generates an inhomogeneous magnetic field 
that causes NMR signals of nearby atoms to experience larger relaxation rates; this phenomenon 
is termed paramagnetic relaxation enhancement (PRE). PRE is distance-dependent so residues 
closest to the TEMPO tag will experience the greatest increases in relaxation rates. By measuring 
the paramagnetic relaxation contribution to the transverse relaxation rates of amide protons, the 
location of the reducing end of the bound ligand can be determined with high sensitivity. Both 
N40 and PBr DBPAs were probed with TEMPO-labeled heparin dp6, and the PRE effect on each 
residue was quantified by measuring changes in transverse relaxation rates of amide protons after 
the TEMPO radical was reduced by ascorbic acid. Due to the weak interactions of N40 DBPA 
with GAGs, the PRE effect was not significant even at a protein-ligand ratio of 6 (Figure S5). On 
the other hand, PBr DBPA experienced significant perturbations after addition of only two molar 
equivalents of the TEMPO-labeled heparin dp6 ligand. Figure 7 shows the residue-specific PRE 
of each backbone amide proton in PBr. The residues that showed the highest PRE were found 
near Site 1(I45, K46, A49, and K79) and Site 2 (E73). These residues are concentrated on helices 
1 and 2, indicating that the reducing end of heparin was near these helices. In contrast, the same 
ligand only produced strong PRE effect in the linker residues (N59 and F60) of B31 DBPA. 
Besides residues in helices one and two of PBr DBPA, A144 in the short linker between helices 
four and five also showed a large PRE effect that could indicate either the existence of another 
weak GAG-binding epitope or non-specific interactions.  
 
Interactions of PBr DBPA mutants with GAGs 
The structure of PBr DBPA and the ligand-binding perturbation analyses suggest PBr 
DBPA most likely possesses two GAG-binding sites. Site 1 is located at the same location as the 
major GAG-binding epitopes of B31 and N40 DBPAs. However, another cluster of basic amino 
acids on the other side of the helices 2 and 5 as Site 1 can also be found. This cluster is made up 
of residues K44, K77, K81, K173 and K176. To determine the contribution of each site to GAG 
binding, mutants of PBr DBPA missing either Site 1 or Site 2 basic amino acid clusters were 
created. In the Site 1 mutant, K79, K130 and K160, three basic amino acids that were found in 
the pocket and showed large changes in either chemical shift mapping analysis or PRE 
perturbation, were mutated to Ser. In Site 2, residues K77, K81, K173 and K176 were mutated to 
Ser. Although these residues did not show large chemical shift perturbations themselves, residues 
around them (L76, L175 and E177) did experience either large chemical shift migrations or 
TEMPO-induced PRE effects. To further dissect the contributions of each basic amino acid pairs 
in Site 2 to GAG binding, Site 2a (K77,81S) and Site 2b (K173,176S) mutants were also created. 
GAG-binding affinities of the mutants were evaluated using NMR titrations, GMSA and ELISA. 
In NMR titrations, each mutant was titrated with heparin dp6 in the same manner as WT PBr to 
determine the effect of mutations on KD of binding. Table 2 lists the apparent heparin dp6 
interaction KDs of these mutants. As expected, mutations in PBr DBPA’s Site 1 significantly 
reduced the chemical shift changes of residues around Site 1 (A49, T64 and G133) after addition 
of heparin dp6 (Figure S6). However, the apparent KD estimated from residues near Site 2 is still 
approximately 0.1 mM, similar to WT PBr (Figure S7). Likewise, mutations of residues K77, 
K81, K173 and K176 in Site 2 to Ser scarcely changed KDs of Site 1 residues, but greatly 
reduced heparin-induced chemical shift changes of Site 2 residues. In particular, KDs derived 
from chemical shift changes of T64, K130 and G133, residues found close to Site 1, decreased 
from > 1 mM to ~ 0.5 mM (Table 2, Figure S7). These observations indicate that both sites are 
involved in binding GAGs but act independently so that when one site is removed, the other site 
retains its GAG affinity. To confirm that K77 and K81 acted synergistically with K173 and K176 
in binding GAGs, Site 2a mutants were titrated with heparin dp6, and significant decreases in 
heparin-induced chemical shift changes observed in C-terminal residues A179 and A182 were 
observed, and KDs estimated using these residues increased from ~0.4 mM to 0.8 mM (Table 2, 
Figure S7). Mutations of K173 and K176 to Ser (Site 2b mutant) completely eliminated chemical 
shift changes A179 and A182 (Figure S6).  
To estimate the contributions of each epitope to PBr DBPA’s GAG-binding activity, 
GMSA and ELISA were carried out on WT PBr and the mutants at physiological pH. Heparin 
dp8 GMSA showed that, after addition of 1 molar equivalent of protein, a significant fraction of 
heparin dp6 fragments is bound to WT PBr DBPA, whereas very little of the fragments are 
bound to the Site 1, full Site 2 and Site 2b mutants, but the Site 2a mutant showed reduced, but 
consistent shifting of heparin dp8 fragments (Figure 8). These results indicate both sites 
contribute significantly to GAG binding by PBr DBPA. However, residues K173 and K176 of 
Site 2 are more important in promoting GAG binding than K77 and K81.  
The GMSA results are also consistent with the heparin ELISA assays in which surface 
bound native heparin polysaccharides were probed with His-tagged WT PBr DBPA and mutants. 
ELISA assays showed that the four mutants bound to heparin with much lower efficiency than 
WT PBr DBPA (Figure 9). This includes the Site 2a mutant, which showed significant affinity 
for heparin dp8 in the GMSA. The discrepancy the Site 2a mutant showed in GMSA and ELISA 
is most likely due to methodology differences between GMSA and ELISA. In particular, the rate 
of dissociation of the GAG-Site 2a mutant complex maybe significantly higher than between 
GAG and WT PBr such that majority of Site 2a mutants are actually washed off during ELISA. 
On the other hand, absorbances of wells coated with mutant PBr DBPAs are slightly higher than 
control, implying that mutations of a single GAG-binding site in PBr DBPA did not completely 
eliminate PBr DBPA’s affinity for intact heparin. 
We also performed competitive heparin-binding ELISA between N40 and PBr DBPAs 
using biotinylated N40 DBPA as a reporter. Our competition assay shows that all PBr DBPA 
variants, including mutants with the weakest GAG affinities were able to displace N40 DBPA 
effectively in the concentration ranges tested (Figure 10). Furthermore, competition assay 
performed using His-tagged PBr DBPA variants as the reporter revealed that N40 DBPA was not 
able to significantly reduce the amount of heparin-bound PBr DBPA variants even when the N40 
DBPA concentration is twice as high as PBr DBPAs (Figure S8). This shows PBr DBPA’s 
affinity for heparin is considerably higher than N40 DBPA, such that loss of one of its GAG 
binding sites still left the protein with higher GAG affinity than WT N40 DBPA.  
 
Discussion 
 
 Because of the important role DBPA plays in establishing early Borrelia spirochetes’ 
colonization [33], understanding how sequence variability in the protein influences its specificity 
and affinity for GAGs is crucial to providing a rational explanation for differing pathogenicities 
of different strains of Borrelia spirochetes. While there have been many structural studies 
conducted on DBPAs from strains B31 and N40 of Borrelia burgdorferi, other strains, such as 
PBr, have not been well-studied, making it difficult to rationalize variations in their biological 
activities. Structural analysis and characterization of GAG interactions for N40 and PBr DBPAs 
carried out here explain how PBr DBPA’s unique structural characteristics allow it to bind GAGs 
with greater affinity than B31 and N40 DBPAs. In particular, both B31 and N40 DBPA have a 
disulfide bond that tethers the C-terminal tail to helix 5. In contrast, PBr DBPA is devoid of both 
cysteine residues required to form this disulfide bond. As a result, its C-terminus is placed away 
from Site 1, allowing the formation of the secondary GAG-binding site by placing residues K173 
and K176 on helix 5 close to residues K77 and K81 on helix 2. This site could not have formed 
without the alternate orientation of the C-terminus.  
Besides the differing positions of the C-termini, the linker between helices 1 and 2 in PBr 
DBPA is also more structured than B31 and N40 DBPAs. The significance of this difference lies 
in the fact that the flexible, unstructured linkers found in B31 and N40 DBPAs are positioned 
directly above Site 1 and may hinder GAGs from accessing the GAG-binding pocket. PBr 
DBPA’s more compact linker leaves more of Site 1 exposed, giving GAG ligands more access to 
Site 1. This observation is compatible with the heparin dp6-TEMPO perturbation data for PBr 
DBPA, which showed that the reducing end of heparin dp6 interacts with residues on helices 1 
and 2, indicating that the fragment was able to enter the pocket. In comparison, linker residues in 
B31 DBPA were the ones affected most significantly by PRE[14] while there were very little 
PRE effects on N40 DBPA residues. Finally, the apparent heparin dp6 KD of PBr’s Site 1, in the 
absence of Site 2, is much higher than that of N40 DBPA (0.4 mM vs > 4 mM), even though 
distributions of basic amino acids in both pockets are similar (Figure S9). These data show that 
the obstruction of the pocket may be an important factor in determining the GAG-affinity of Site 
1. This model of DBPA-GAG interaction also explains why the basic amino acid cluster (the 
BXBB motif) in the linker of B31 DBPA is important to the protein’s affinity for GAGs: it 
compensates for the reduced access to the binding pocket by providing additional binding 
epitopes for GAGs, thereby increasing B31 DBPA’s affinity for GAGs. In contrast, N40 is 
missing both Site 2 as well as the basic amino acid cluster in the linker, resulting in a much lower 
affinity for GAGs despite the fact that the number of basic amino acids in N40 DBPA is almost 
identical to B31 DBPA (28 basic amino acids in N40 DBPA vs. 29 basic amino acids in B31). 
While PBr does not contain the basic amino acid cluster in its linker, PBr DBPA compensates for 
this by having a second GAG-binding site and a retracted linker that allows more access to Site 
1.  
In addition, titrations of PBr DBPA mutants with heparin dp6 showed that the two sites are 
independent of each other. This independence is manifested in the fact that elimination of either 
site has no effect on GAG affinity of the remaining site. In fact, the apparent KDs of binding 
estimated from several residues close to Site 1 decreased significantly after mutations in Site 2, 
implying Site 1’s affinity for GAGs increased with elimination of Site 2. Interestingly, the 
magnitudes of decreases were larger than decreases predicted with the assumption that Site 2 
only binds a single ligand. Specifically, because the ligand concentration is much higher than the 
protein concentration throughout the titration, an active Site 2 should not change the 
concentration of free ligand significantly if Site 2 only binds a single ligand. One possible 
explanation for the unexpected large changes in Site 1 KDs is that Site 2 is capable of 
simultaneously binding more than one ligand, thus can bind a higher amounts of GAG fragments 
than expected. Its elimination would increase the concentration of free GAG ligand more than 
expected. Another possibility is that mutations of Site 2 produced significant changes in the 
structure of PBr DBPA, leading to enhanced ligand affinity in Site 1. However, this hypothesis is 
not supported by the fact that the 
15
N-edited HSQCs of both Site 2 mutants are very similar to 
WT PBr DBPA (Figure S6), indicating the structures has not changed significantly in these 
mutants. Even though an accurate KD of interaction is not known for Site 1 of PBr DBPA, the 
dramatic decreases in PBr DBPA mutants’ affinities for heparin in ELISA indicate both sites are 
important for PBr DBPA under physiological conditions. It also highlights the importance of 
multivalent effect to protein-GAG interactions. Multivalency will be especially critical in vivo 
where native GAG chains are capable of binding multiple epitopes simultaneously. 
These structures of PBr, B31 and N40 DBPAs show that despite having similar 
topologies, subtle changes in sequences can result in significant structural variations that 
contribute greatly to differences in the adhesion activities of the protein. Characterization of their 
structures and GAG interactions can therefore provide crucial insights into how strain variations 
may contribute to the pathogenicity and offer hypotheses for further in vivo experimentation. 
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Table 1. Structural Statistics for the Ensemble of N40 and PBr Structures 
 N40 PBr 
No. of NOE-based distance constraints   
Total 1732 1440 
Intraresidue (i = j) 351 398 
Sequential (|i – j| = 1) 468 502 
Medium-range (1 < |i – j| < 5) 419 310 
Long-range 494 230 
NOE constraints per restrained residue
a
 10.7 8.8 
No. of dihedral angle constraints 260 280 
Total no. of structures computed 100 100 
No. of structures used 10 10 
Residual constraint violations
b
   
No. of distance violations per structure   
0.1-0.5 Å 32.2 41.3 
>0.5 Å 0 1 
No. of dihedral angle violations per structure   
1-10° 5.6 9.0 
>10° 0 0 
RMSD   
All backbone atoms   
All 1.3 Å 2.5 Å 
Ordered
c 
0.7 Å 0.6 Å 
All heavy atoms   
All 1.7 Å 2.7 Å 
Ordered
c 
1.3 Å 1.1 Å 
Ramachandran plot summary from Procheck
d
 (%)   
Most favored regions 93.2 90.4 
Additionally allowed regions 5.9 9.3 
Generously allowed regions 0.3 0.3 
Disallowed regions 0.6 0.0 
a
 There are 162 residues (for N40) and 163 residues (for PBr) with conformationally 
restricting constraints.  
b
 Calculated for all constraints for the given residues, using sum over 
r
-6
.  
c 
Residues with sum of phi and psi order parameters > 1.8. Ordered residue ranges for 
N40 are the following: 35-59,79-104, 112-133,136-148 and 152-183. Ordered residue 
ranges for PBr are the following: 34-52, 73-100,106-126,130-141 and 147 to 179.  
d
 
Residues selected on basis of dihedral angle order parameter, with S(phi)+S(psi) ≥ 1.8.  
Selected residue ranges for N40 and PBr are the same as the ordered residue ranges. 
 
  
 Table 2. KD of mutant PBr-heparin dp6 interaction from calculation using chemical shift 
changes from residues K130 (Site 1) and A179 (Site 2). 
PBr DBPA 
KD (mM) 
Site 1 (K130) Site 2 (A179) 
WT ~ 1.2 ~ 0.4 
Site 1 Mutant -- 0.1 ± 0.1 
Site 2 Mutant 0.5 ± 0.1 -- 
Site 2a Mutant 0.2 ± 0.1 0.79 ± 0.1 
Site 2b Mutant 0.4 ± 0.1 -- 
 
  
 Figure Legends 
Figure 1. Ensemble of the 10 lowest-energy structures of (A) N40 DBPA and (B) PBr DBPA in 
solution. Helix 1 (residues 33-60 for N40, residues 30-50 for PBr) is colored green. Helix 2 
(residues 79-105 for N40, residues 72-99 for PBr) is colored blue. Helix 3 (residues 112-131 for 
N40, residues 106-126 for PBr) is colored red. Helix 4 (residues 137-145 for N40, residues 131-
141 for PBr) is colored cyan. Helix 5 (residues 157-183 for N40, residues 147-174 for PBr) is 
colored purple. The structured linker (residues 56-67) of PBr is colored yellow, and the disulfide 
bond anchoring the C-terminus to helix 5 in N40 is colored orange. The schematic topology of 
N40 is shown at the bottom left and PBr, the bottom right. 
 
Figure 2. Sequence alignment of B31, N40, and PBr DBPAs. The helical regions of each protein 
are highlighted in black. The structured linker found in PBr DBPA is notated in grey. 
 
Figure 3. Superimposition of B31 (cyan), N40 (green) and PBr (tan) DBPA structures. The 
linker in PBr DBPA is more retracted than the linkers in B31 and N40 DBPAs. The C-terminus 
in PBr DBPA is also not tethered to helix 5 by a disulfide bond as it is in B31 and N40 DBPAs. 
 
Figure 4. (A) Electrostatic potential surface map of N40 DBPA. Red indicates acidic regions and 
blue, basic regions. (B) Ribbon diagram of N40 DBPA showing the protein in the same 
orientation as Figure 1A. 
 
Figure 5. Electrostatic potential surface maps of PBr DBPA in the same orientation as Figure 1B 
(A) and rotated 180° about the vertical axis (C). Red indicates acidic regions and blue, basic 
regions. Ribbon diagrams of PBr DBPA showing the protein in the same orientation as Figure 
1B (C) and rotated 180° about the vertical axis (D). 
 
Figure 6. Titrations of WT N40 and PBr DBPAs with heparin dp6. (A) 
15
N-HSQC overlays of 
WT N40 DBPA in the presence of increasing concentrations of heparin dp6.The blue contour 
represents the initial HSQC spectrum of N40 in the absence of heparin dp6. Each subsequent 
colored contour represents the HSQC spectrum of N40 at the following concentrations of heparin 
dp6: 0.75, 1.50, 2.25, 3.00, and 3.75 mM. The concentration of N40 was 0.15 mM. Residues 
experiencing a large migration are indicated with the residue number and the direction of 
migration. Normalized chemical shift changes for the residues are shown on the left. The 
residues perturbed the most by the addition of heparin dp6 are notated on each plot. The 
secondary structure for each protein is displayed at the top of each plot. (B) Titration of 0.15 mM 
WT PBr DBPA with heparin dp6. The color scheme is identical to that of N40 DBPA titration 
except for the following: each subsequent colored contour after the blue contour (absence of 
heparin dp6) represents the HSQC spectrum of PBr at the following concentrations of heparin 
dp6: 0.3, 0.6, 0.9, 1.2, 1.5, and 2.1 mM. 
 
Figure 7. (A) Residue-specific PRE on backbone amide protons of WT PBr from TEMPO-
labeled heparin dp6. Residues on helices 1 and 2 (K46, A49, E73, and K75) experienced larger 
PRE effects when probed with TEMPO-heparin dp6. (B) Ribbon diagram of WT PBr DBPA 
with the residues experiencing the greatest PRE effect colored in red. 
 
Figure 8. GMSA of heparin dp8 in the presence of increasing concentrations of WT PBr DBPA, 
Site 1 Mutant, Site 2 Mutant, Site 2a Mutant, and Site 2b Mutant. 
 
Figure 9. Effect of mutations in PBr DBPA on GAG-binding as determined by ELISA. 
Mutations in either GAG-binding epitope reduced PBr DBPA’s affinity for GAGs. 
 
Figure 10. Effect of PBr DBPA on binding of biotinylated N40 DBPA to heparin coated 
microwell plates. Each well contains 4 μg of biotinylated N40 DBPA and either 0, 2, 4 or 6 μg of 
PBr DBPA variants. All PBr variants easily competed off biotinylated N40 DBPA. 
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